ERBB2 and non-small cell lung carcinoma: In particular, the open-label, multicenter phase II DESTINY-Lung 01 trial (NCT03505710) (15) in 2022 evaluated the efficacy and safety of 6.4 mg/kg DS-8201 in 91 patients with metastatic HER2-mutant NSCLC refractory to standard treatment.